As our understanding of the mechanisms of cancer treatment has increased, a growing
number of studies demonstrate pathways through which DNA damage repair (DDR) affects …

The application of immunotherapy for cancer treatment is rapidly becoming more
widespread. Immunotherapeutic agents are frequently combined with various types of …

For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable
molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L) 1 …

Breast cancer has a high occurrence rate globally and its treatment has demonstrated
clinical efficacy with the use of systemic chemotherapy and immune checkpoint blockade …

Abstract Background Biliary tract cancers (BTCs) comprise a heterogeneous group of
aggressive malignancies with unfavorable prognoses. The benefit of chemotherapy seems …

Simple Summary Immunotherapy has revolutionized cancer care across different cancer
types. Unfortunately, leiomyosarcoma does not seem sensitive to the first-generation …

Recent studies have found that the protein encoded by the FDX1 gene is involved in
mediating Cuproptosis as a regulator of protein lipoylation and related to immune response …

Background: Transgelin-2 (TAGLN2) has long been regarded as an actin-binding protein
that modulates actin gelation and controls actin cytoskeleton dynamics. However, recent …

Background DNA damage repair (DDR) may affect tumorigenesis and therapeutic response
in hepatocellular carcinoma (HCC). Long noncoding RNAs (LncRNAs) can regulate DDR …

Immune checkpoint blockade (ICB) therapy can improve the survival of cancer patients with
a high tumor mutation burden (TMB-H) or deficiency in DNA mismatch repair (dMMR) in their …